Live Investor briefing, page-23

The European bit was in relation to PTX100 and the filing for Orphan Status in Europe as per the following slide:




Seems that with PTX100 nearing the final readout (and Steve mentions that it's due very soon), 100 is garnering a lot of attention... and rightly so given the following stats:



It seems that the big decision will be which of the two TCL diseases to take through to the next phase (registration trial)... will it be PTCL or CTCL. Combination drug trials aren't out of the question either.

I think Steve makes its abundantly clear that its PTX100 which will be the first major catalyst for the company this year and "very soon" (whatever that may equate to in real time).